anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 22.5 mg.
Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
In adult patients with primary (thyroidal) hypothyroidism, serum TSH levels (using a sensitive assay) alone may be used to monitor therapy. The frequency of TSH monitoring during levothyroxine dose titration depends on the clinical situation but it is generally recommended at 6-8 week intervals until normalization. For patients who have recently initiated levothyroxine therapy and whose serum TSH has normalized or in patients who have had their dosage of levothyroxine changed, the serum TSH concentration should be measured after 8-12 weeks. When the optimum replacement dose has been attained, clinical (physical examination) and biochemical monitoring may be performed every 6-12 months, depending on the clinical situation, and whenever there is a change in the patient's status. It is recommended that a physical examination and a serum TSH measurement be performed at least annually in patients receiving Levothyroxine Sodium Tablets, USP. (see WARNINGS, PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Progression of ill health and death trajectories is different for children with a non-oncology diagnosis. As previous research has focused primarily on children with cancer diagnoses, this scoping review explored what factors influence the parent and/or child's choice of place of death for a child with a non-oncological complex care condition, when death is expected. Eighteen papers were identified considering the preferred place of death. The findings were themed into 1. Diagnostic Factors; 2. Home Factors; 3. Socio-economic Factors; 4. Parent Factors. In conclusion, informed discussions with families that recognize the reason for, and the impact of their choices, are necessary not only for the preferred place of death but also end of life care.
A modular energy system for use in a surgical environment includes a plurality of functional modules including at least an initial module, a functional module, and a terminal module. Each of the plurality of modules has a module control circuit, and a local data bus. An internal data bus is composed of a serial array of the local data busses of the modules. The local data bus may includes a communication switch, a first switch data path between the communication switch and the module control circuit, a second switch data path in communication with the communication switch, and a third switch data path in communication with the communication switch. The third switch data path of a module N is in communication with a second switch data path of a module N+1. The system further includes a termination unit in communication with the third data path of the terminal module.
PROBLEM TO BE SOLVED: To perform suitable drying regardless of the presence and the degree of viscosity of a substance to be dried, to produce a large quantity of dried substance in a short time, and to prevent the occurrence of thermal denaturation of the substance to be dried by providing a flow passage through which an air current flows and which dries a frozen solidified substance by the air current. SOLUTION: A granulated solidified substance 2 prepared by bringing the freeze up solidified substance of a substance to be dried into a granulated state is sprayed in an air current A, ventilated through a pipe 1, through a spray nozzle 6. When the moisture content of the solidified substance 2 is vaporized and dried, a mixture air current of the dried substance 4 and exhaust gas 5 is collected in a cyclone 3, wherein the mixture air current is separated to obtain the dried substance 4 through a collection port 7 and the exhaust gas 5 is exhausted. The air current A is not especially limited. Normal air may be used but dried air is preferable. Further, when drying is effected in inactive atmosphere, such as nitrogen gas, carbonic acid gas, and argon gas, there is no risk of explosion occurring and even the mixtured gas current may be used.
PURPOSE OF REVIEW: To provide a summary of the visual manifestations and cranial neuropathies seen in Lyme disease.
RECENT FINDINGS: Lyme facial palsy remains the most common manifestation of Lyme neuroborreliosis. Recent investigations show likely evidence of vagal involvement in Lyme disease.
SUMMARY: The literature on Lyme neuroborreliosis continues to evolve. Lyme disease can affect nearly any cranial nerve in addition to causing various headache syndromes. The most common manifestation is Lyme disease facial palsy, occurring in up to 5-10% of patients with documented Lyme disease. Headache syndromes are common in the context of facial palsy but can occur in isolation, and more specific headache syndromes including trigeminal and geniculate neuralgias can occur rarely. Signs and symptoms indicative of vestibulocochlear nerve involvement are relatively common, although it could be that these represent other vestibular involvement rather than a specific cranial neuropathy. Optic neuritis is a controversial entity within Lyme disease and is likely overdiagnosed, but convincing cases do exist. Physicians who see any cranial neuropathy, including optic neuritis, in an endemic area can consider Lyme disease as a possible cause.
A variety of therapies for the treatment of sprains has emerged as they occur advances in technological applications. Therapy with coherent and non-coherent light is a treatment modality for a variety of musculoskeletal injuries. The main benefits certificates for phototherapy are the reduction of nociceptive processes, tissue remodeling, among others. The aim of the present paper is to analyze the changes caused by the use of LED (627 +/- 10 nm) with an energy density of 10 J / cm2 in 40 subjects divided into two groups (placebo and LED). All volunteers participating in this study had ankle inversion sprain grade II treated with the price technique. The study was performed in six days. And the results were verified by review of all individuals, through the Visual Analogue Scale (VAS) of pain, McGill Pain Questionnaire and Titrimetry. Measurements were performed at first, third and sixth day's of treatment.
One of the greatest frequent types of malignancy is gastric cancer (GC). Metastasis, an essential feature of stomach cancer, results in a high rate of mortality and a poor prognosis. However, metastasis biological procedures are not well recognized. Long non-coding RNAs (lncRNAs) have a role in numerous gene regulation pathways via epigenetic modification as well as transcriptional and post-transcriptional control. LncRNAs have a role in a variety of disorders, such as cardiovascular disease, Alzheimer's, and cancer. LncRNAs are substantially related to GC incidence, progression, metastasis and drug resistance. Several research released information on the molecular processes of lncRNAs in GC pathogenesis. By interacting with a gene's promoter or enhancer region to influence gene expression, lncRNAs can operate as an oncogene or a tumor suppressor. This review includes the lncRNAs associated with metastasis of GC, which may give insights into the processes as well as potential clues for GC predicting and tracking.
The present disclosure provides methods for preparing vesicles. In some embodiments, the methods involve providing a molten mixture of vesicle forming lipids and then adding the molten mixture to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. In other embodiments, the methods involve providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by melting vesicle-forming lipids to produce a molten lipid mixture and then lyophilizing the molten lipid mixture. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.
The invention belongs to the technical field of traditional Chinese medicine preparation method, and provides a preparation method of a traditional Chinese medicine used for treating decubitus caused by blood-deficiency. According to existing technologies, decubitus caused by blood-deficiency is commonly treated by using sulfonamides and antibiotics, which cause severe side-effects. The technical scheme of the invention is that: traditional medicines of prepared rehmannia root, tuber fleeceflower root, ligusticum, white peony root, cassia pulp, ginseng, human milk, common jujube, common yam rhizome, wheat, different leaves pseudostellaria root tuber, balck-bone silky fowl, wild cabbage, dried longan pulp, largehead atractylodes rhizome, radix paeoniae alba, American ginseng, ligusticum, lotus seed, pilose asiabell root, sharpleaf galangal fruit, mongolian milkvetch root, Siberian solomonseal rhizome, nonglutinous rice, dried ginger, edible bird nest, and licorice are decocted by using a mild fire; the obtained solution is filtered, a slag is removed, and the obtained medicine liquid is the traditional Chinese medicine used for treating decubitus caused by blood-deficiency. The method is advantaged in that: toxic and side-effects of the traditional Chinese medicine liquid are low; a treatment course is short; and a recovery rate is high. According to the invention, a good effect can be obtained with the cooperation of monarch and minister medicines. A traditional Chinese medicine preparation is adopted, such that adverse reactions caused by western medicines are avoided.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to surgery, and deals with treatment of purulent arthritis. For this purpose carried out is intra-joint introduction of not less than 10 ml of anolyte 0.3% NaCl with neutral Ph 7.3-7.7 and AFP +700-1100 mV. Said anolyte is introduced also peraorticularly in volume not less than 3 ml. Treatment course constitutes not less than nine days. ^ EFFECT: method increases treatment efficiency, including on the background of post-traumatic hemarthrosis, synovitis, in absence of toxic action on joint and on surrounding it tissues and without application of pharmaco- and physiotherapy. ^ 5 tbl
FIELD: genetics, molecular biology. SUBSTANCE: invention relates to vaccine for prevention and control over animal diseases involving pseudorabies virus containing glycoprotein gp 50 and mutation in gene gp 50. Vaccines can be used against Aujeszky's disease (pseudorabies) or against other animal diseases if mutation is an insertion containing heterological gene that encodes antigen corresponding to this disease. Pseudorabies virus can contain additionally at least one mutation in gene gp 63 or g1. These vaccines can not be transferred from vaccinated to nonvaccinated animals. EFFECT: enhanced effectiveness of vaccines.
A Randomized control study of 3 month period will be conducted at Riphah International University Faisalabad. Patients will be enrolled by purposive sampling based on pre-defined inclusion and exclusion criteria. Patients were randomly allocated into groups. The Patients of group A will receive scaphoid, hamate mobilization with kinesio taping and group B will receive neural mobilization with kinesiotaping. Group A will receive neural mobilization and Group B will receive scaphoid and hamate moilization. The Patient's outcome will be distinguished by Visual Analogue scale and the data of the patients will be noted pre-treatment and post-treatment. Informed consent will be taken from each patient. Data entry and analysis will prepare through Statistical Package of Social Sciences Version 20.
A sheet wound dressing formed of cross linked keratin. An insoluble, largely Beta keratin fraction from human hair is acidified to a low pH, preferably less than about 3, which partially solubilizes the keratin by weakening hydrogen bonds. The suspension is added to base, such as ammonium hydroxide, forming a slurry. The slurry is cast directly onto a flat surface, allowing the re-formation of cross-links including hydrogen bonds and disulfide bonds. The resulting cross-linked keratin sheet can be used as a sheet wound dressing or as a scaffolding for growth of cells. The insoluble keratin can be derived from human hair which is washed, rinsed, dried, chopped and treated with peracetic acid to break some accessible disulfide linkages. The treated hair is filtered, rinsed, dried, and ground into a keratin powder. The keratin powder is suspended in a mixture of ammonium hydroxide and ammonium thioglycollate and heated sufficiently to dissolve the soluble keratin fraction, followed by cooling and centrifugation to concentrate the insoluble, largely Beta keratin fraction.
Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg clomiphene citrate. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, such as in patients with polycystic ovary syndrome (see WARNINGS; Ovarian Hyperstimulation Syndrome).

The patient should be evaluated carefully to exclude pregnancy, ovarian enlargement, or ovarian cyst formation between each treatment cycle.

If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has had no recent uterine bleeding. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment.

If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended.

The majority of patients who are going to ovulate will do so after the first course of therapy. If ovulation does not occur after three courses of therapy, further treatment with clomiphene citrate is not recommended and the patient should be reevaluated. If three ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses does not occur after an ovulatory response, the patient should be reevaluated. Long-term cyclic therapy is not recommended beyond a total of about six cycles (see PRECAUTIONS).
Hydrocodone bitartrate extended-release tablets contain hydrocodone, a Schedule II controlled substance. As an opioid, hydrocodone bitartrate extended-release tablets expose users to the risks of addiction, abuse, and misuse. Because extended-release products such as hydrocodone bitartrate extended-release tablets deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of hydrocodone present  [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed hydrocodone bitartrate extended-release tablets. Addiction can occur at recommended doses and if the drug is misused or abused. 

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing hydrocodone bitartrate extended-release tablets, and reassess all patients receiving hydrocodone bitartrate extended-release tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the prescribing of hydrocodone bitartrate extended-release tablets for the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as hydrocodone bitartrate extended-release tablets, but use in such patients necessitates intensive counseling about the risks and proper use of hydrocodone bitartrate extended-release tablets along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Abuse or misuse of hydrocodone bitartrate extended-release tablets by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of the hydrocodone and can result in overdose and death [see Drug Abuse and Dependence (9.2), and Overdosage (10)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing hydrocodone bitartrate extended-release tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
Methods of extracting and removing hyperpolarized gas from a container include introducing an extraction fluid into the container to force the hyperpolarized gas out of an exit port. The hyperpolarized gas is forced out of the container separate and apart from the extraction fluid. Alternatively, if the fluid is a gas, a portion of the gas is mixed with the hyperpolarized gas to form a sterile mixed fluid product suitable for introduction to a patient. An additional method includes engaging a gas transfer source such as a syringe to a transport container and pulling a quantity of the hyperpolarized gas out of the container in a controlled manner. Another method includes introducing a quantity of liquid into a container and covering at least one predetermined internal surface or component with the liquid to mask the surfaces and keep the hyperpolarized gas away from the predetermined internal surface, thereby inhibiting any depolarizing affect from same. Examples of surfaces or components suitable for masking include valves, seals, and the like. Yet another extraction method includes expanding a resilient member inside the container to force the hyperpolarized gas to exit therefrom. Containers include a resilient member positioned in fluid communication with the hyperpolarized gas in the container. An additional container includes inlet and outlet ports in fluid communication with the chamber and positioned on opposing sides or end portions of the container. Another container includes a port configured to receive a portion of a syringe therein. An additional aspect of the disclosure relates to calibration methods and apparatus for identifying the hyperpolarization status of the gas.
Filippi syndrome is a rare genetic disorder characterized by growth and neurodevelopmental delays, dysmorphism, and selective limb abnormalities. Although the syndrome was described approximately four decades ago, only a few families with molecularly confirmed diagnoses have been reported. In this article, we present three new patients of Filippi syndrome with unusual clinical and genetic aspects. These patients exhibited novel clinical features that have not previously been associated with Filippi syndrome, including renal hypoplasia/aplasia, renal cysts, renal cortical thinning, hypomelanotic, and hypermelanotic macules. All three patients had homozygous frameshift variants of the CKAP2L gene, specifically NM_152515.3: c.554_555del, c.981_982del, and c.1463_1467del, with the second being a novel variant. Given the limited number of reported Filippi syndrome patients to date and the ongoing discovery of new clinical aspects of the disease, exploring its potential connection with kidney and skin pigmentation abnormalities could be valuable for future research.
Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
FIELD: glutamic acid derivatives. SUBSTANCE: the desired compound is prepared from glutamic acid and p-aminomethylbenzoic acid under boiling in an aqueous medium. The yield is 87%, mp 204-205 C. The empirical formula: CHNO·LD>2000 mg/kg. The tests show that the compound thus obtained have, in addition to said properties, an antiaggregative effect. EFFECT: new compounds of said class having improved activity. 5 tbl
OBJECTIVE: This randomized clinical trial evaluated the efficacy of Mindfulness-Oriented Recovery Enhancement (MORE) among past and present U.S. military personnel with prescriptions for long-term opioid therapy for chronic pain.
METHODS: In this clinical trial, 230 past and present military personnel with prescriptions for long-term opioid therapy were randomized in a 1:1 ratio to MORE or supportive psychotherapy (initially delivered in person and then via videoconferencing after the onset of the COVID-19 pandemic). Primary outcomes were chronic pain, measured by the Brief Pain Inventory, and aberrant drug-related behaviors, measured by the Current Opioid Misuse Measure, through 8 months of follow-up. Opioid dose was a key secondary outcome. Other outcomes included psychiatric symptoms, catastrophizing, positive affect, ecological momentary assessments of opioid craving, and opioid attentional bias.
RESULTS: MORE was superior to supportive psychotherapy through the 8-month follow-up in reducing pain-related functional interference, pain severity, and opioid dose. MORE reduced daily opioid dose by 20.7%, compared with a dose reduction of 3.9% with supportive psychotherapy. Although there was no overall between-group difference in opioid misuse, the in-person MORE intervention outperformed supportive psychotherapy for reducing opioid misuse. MORE reduced anhedonia, pain catastrophizing, craving, and opioid attentional bias and increased positive affect to a greater extent than supportive psychotherapy. MORE also modulated therapeutic processes, including mindful reinterpretation of pain sensations, nonreactivity, savoring, positive attention, and reappraisal.
CONCLUSIONS: Among past and present U.S. military personnel, MORE led to sustained decreases in chronic pain, opioid use, craving, and opioid cue reactivity. MORE facilitated opioid dose reduction while preserving adequate pain control and preventing mood disturbances, suggesting its utility for safe opioid tapering.
A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.